ReviewGenes2024
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing.
Open access · goldAbstract readReview
In one paragraph
Review in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
22.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Repair of DNA double-strand breaks after low radiation doses in childhood cancer survivors and matched cancer-free individuals.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Multigene panel testing reveals the spectrum of non-BRCA germline variants in BRCA1/2-negative breast, ovarian, and prostate cancer patients from a Turkish cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- DeepSynBa: actionable drug combination prediction with complete dose-response profiles.Bioinformatics (Oxford, England) · 2026Article
- Multi-omics analysis in suspected hereditary breast and ovarian cancer cases reveals novel candidate susceptibility factors.NPJ breast cancer · 2026Article
- From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management a systematic review.Biochemistry and biophysics reports · 2026Review
- The Role of Mesothelin in Gynecological Tumors and Its Significance in Targeted Therapies-A Review.Cancers · 2026Review
- Harnessing archaeogenetic for cancer therapy: bridging ancient DNA insights with modern therapeutic innovations.Clinical epigenetics · 2026Review
- Deciphering the immunological landscape of HR + metastatic breast cancer: insights from single-cell transcriptomics.Human cell · 2026Article
- Role of laser therapy in enhancing chemotherapy efficiency in breast cancer: low level laser therapy, photochemotherapy, and photodynamic therapy as promising treatments.Lasers in medical science · 2026Review
- Breast cancer: taxonomy, distribution analysis, risk factors, predictive biomarkers, and modern treatment method.Apoptosis : an international journal on programmed cell death · 2026Review
- Hereditary ovarian cancer.Discover oncology · 2026Review
- Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers.Clinical and translational medicine · 2026Review
- Review
- Double jeopardy: howFrontiers in cell and developmental biology · 2026Review
- VEGF-Leptin Crosstalk in Breast and Ovarian Cancer: Drivers of Angiogenesis and Progression.Cancer management and research · 2026Review
- A clinical report and analysis of metachronous multiple primary cancers occurred in four sites.Journal of cancer research and clinical oncology · 2025Article
- Article
- Study the impact ofCytotechnology · 2025Article
- Genetic insights into BRCA1/2 associated breast cancer in Türkiye: focus on early-onset and aggressive subtypes.Discover oncology · 2025Article
- Ovarian Cancer-Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors' Molecular Backgrounds.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Valeria BariliDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0000-0001-7711-2156
Enrico AmbrosiniMedical Genetics, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0002-7520-3721
Beatrice BortesiMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Roberta MinariMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0002-4808-0308
Erika De SensiDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0000-0002-2104-4016
Ilenia Rita CannizzaroDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Antonietta TaianiDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0009-0004-4282-6801
Maria MichiaraMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Angelica SikokisMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Daniela BoggianiMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Chiara TommasiDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0000-0002-9230-9288
Olga SerraMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Francesco BonattiMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Alessia AdorniMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Anita LubertoDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Patrizia CaggiatiMedical Genetics, University Hospital of Parma, 43126 Parma, Italy.
Davide MartoranaMedical Genetics, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0002-7572-7031
Vera UlianaMedical Genetics, University Hospital of Parma, 43126 Parma, Italy.
Antonio PercesepeDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0000-0002-3268-6786
Antonino MusolinoDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0000-0002-7979-6261
Benedetta PellegrinoMedical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
University of Parma · IT
Funding
BANDO DI ATENEO PER LA RICERCA 2022 from University of ParmaFondazione Emma ed Ernesto Rulfo per la Genetica Medica
Abstract
Germline variants occurring in
Indexed as
Genes, BRCA2Ovarian NeoplasmsDNA Breaks, Double-StrandedFemaleHumansPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesRecombinational DNA RepairPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesBRCA1 and BRCA2hereditary breast and ovarian cancer (HBOC) syndromehomologous recombination deficiency (HRD)poly (ADP-ribose) polymerase (PARP) inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.